整形外科用バイオマテリアル市場の競合動向

Abstract

Market Highlights:

Valued at over $1 billion in 2004,the US matket for orthopedic biomaterials was comprised of the following segments:

• Bone graft substitutes(BGS)
• Spinal machined bone
• Osteoarticular allografts
• Hyaluronic acid injections
• Emerging growth factor technologies
• Platelet concentration systems
• Autologous chondrocyte implantation

The market for orthopedic biomaterinls is driven by the need for better solutions to aiments and dlseases, such as dagenerative disc disease and osteaarthritis,resulting from an ever increasingly active and aging population.

Better understand the US Orthopedic Biomaterials Market. Receive the most up-to-date data available on procedure volumes and unit sales, market value, and market shares, Contrast effective strategies employed by industry leaders to create and sustain market share.

Table of Contents

TABLE OF CONTENTS

LIST OF EXHIBITS

METHODOLOGY

1.0 ALLO SOURCE

• 1.1 Company Overview
• 1.2 Products Offered
• 1.3 Recent Events⁄Strategy
• 1.4 Financial Overview
• 1.5 S.W.O.T. Analysis
  • 1.5.1 Strengths
  • 1.5.2 Weaknesses
  • 1.5.3 Opportunities
  • 1.5.4 Threats

2.0 BIOMET

• 2.1 Company Overview
• 2.2 Products Offered
  • 2.2.1 Bone Graft Substitutes
  • 2.2.2 Hyaluronic Acid Viscosupplementation
  • 2.2.3 Platelet Concentration Systems
  • 2.2.4 Growth Factors
  • 2.2.5 Machined Bone Products
• 2.3 Recent Events⁄Strategy
• 2.4 Financial Overview
• 2.5 S.W.O.T. Analysis
  • 2.5.1 Strengths
  • 2.5.2 Weaknesses
  • 2.5.3 Opportunities
  • 2.5.4 Threats

3.0 BIOMIMETIC PHARMACEUTICALS

• 3.1 Company Overview
• 3.2 Products Offered
• 3.3 Recent Events⁄Strategy
• 3.4 S.W.O.T. Analysis
  • 3.4.1 Strengths
  • 3.4.2 Weaknesses
  • 3.4.3 Opportunities
  • 3.4.4 Threats

4.0 CERAPEDICS

• 4.1 Company Overview
• 4.2 Products Offered
• 4.3 Recent Events⁄Strategy
• 4.4 S.W.O.T. Analysis
  • 4.4.1 Strengths
  • 4.4.2 Weaknesses
  • 4.4.3 Opportunities
  • 4.4.4 Threats

5.0 DEPUY (A J& J CO. )

• 5.1 Company Overview
• 5.2 Products Offered
  • 5.2.1 Bone Graft Substitutes
  • 5.2.2 Growth Factors
  • 5.2.3 Platelet Concentration Systems
  • 5.2.4 Other
• 5.3 Recent Events⁄Strategy
• 5.4 Financial Overview
• 5.5 S.W.O.T. Analysis
  • 5.5.1 Strengths
  • 5.5.2 Weaknesses
  • 5.5.3 Opportunities
  • 5.5.4 Threats

6.0 FIDIA FARMACEUTICI

• 6.1 Company Overview
• 6.2 Products Offered
  • 6.2.1 Autologous Chondrocyte Implantation
  • 6.2.2 Hyaluronic Acid Viscosupplementation
• 6.3 Financial Overview
• 6.4 S.W.O.T. Analysis
  • 6.4.1 Strengths
  • 6.4.2 Weaknesses
  • 6.4.3 Opportunities
  • 6.4.4 Threats

7.0 GENZYME BIOSURGERY (VERIGEN AG)

• 7.1 Company Overview
• 7.2 Products Offered
  • 7.2.1 Productson the Market
  • 7.2.2 Products in Development
• 7.3 Recent Events⁄Strategy
• 7.4 Financial Overview
• 7.5 S.W.O.T. Analysis
  • 7.5.1 Strengths
  • 7.5.2 Weaknesses
  • 7.5.3 Opportunities
  • 7.5.4 Threats

8.0 ISOTIS ORTHOBIOLOGICS

• 8.1 Company Overview
• 8.2 Products Offered
  • 8.2.1 Bone Graft Substitutes
• 8.3 Recent Events⁄Strategy
• 8.4 Financial Overview
• 8.5 S.W.O.T. Analysis
  • 8.5.1 Strengths
  • 8.5.2 Weaknesses
  • 8.5.3 Opportunities
  • 8.5.4 Threats

9.0 MEDTRONIC SOFAMOR DANEK

• 9.1 Company Overview
• 9.2 Products Offered
  • 9.2.1 Spinal AlloGrafts
  • 9.2.2 Bone Graft Substitutes
  • 9.2.3 Growth Factors
• 9.3 Recent Events⁄Strategy
• 9.4 Financial Overview
• 9.5 S.W.O.T. Analysis
  • 9.5.1 Strengths
  • 9.5.2 Weaknesses
  • 9.5.3 Opportunities
  • 9.5.4 Threats

10.0 MUSCULOSKELETAL TRANSPLANT FOUNDATION

• 10.1 Company Overview
• 10.2 Products Offered
  • 10.2.1 Bone Graft Substitutes
  • 10.2.2 Spinal AlloGrafts
  • 10.2.3 Allofix Cortica l Bone Pinsand Screws
• 10.3 Recent Events⁄Strategy
• 10.4 Financial Overview
• 10.5 S.W.O.T. Analysis
  • 10.5.1 Strengths
  • 10.5.2 Weaknesses
  • 10.5.3 Opportunities
  • 10.5.4 Threats

11.0 ORTHOLOGIC

• 11.1 Company Profile
• 11.2 Products Offered
• 11.2.1 Chrysalin
• 11.3 Recent Events⁄Strategy
• 11.4 S.W.O.T. Analysis
  • 11.4.1 Strengths
  • 11.4.2 Weaknesses
  • 11.4.3 Opportunities
  • 11.4.4 Threats

12.0 ORTHOVITA

• 12.1 Company Profile
• 12.2 Products Offered
• 12.2.1 Bone Graft Substitutes
• 12.3 Recent Events⁄Strategy
• 12.4 Financial Overview
• 12.5 S.W.O.T. Analysis
  • 12.5.1 Strengths
  • 12.5.2 Weaknesses
  • 12.5.3 Opportunities
  • 12.5.4 Threats

13.0 OSTEOTECH, INC

• 13.1 Company Overview
• 13.2 Products Offered
  • 13.2.1 Spinal AlloGrafts
  • 13.2.2 Bone Graft Substitutes
• 13.3 Recent Events⁄Strategy
• 13.4 Financial Overview
• 13.5 S.W.O.T. Analysis
  • 13.5.1 Strengths
  • 13.5.2 Weaknesses
  • 13.5.3 Opportunities
  • 13.5.4 Threats

14.0 Q-MED

• 14.1 Company Overview
• 14.2 Products Offered
  • 14.2.1 Hyaluronic Acid Viscosupplementation
• 14.3 Recent Events⁄Strategy
• 14.4 Financial Overview
• 14.5 S.W.O.T. Analysis
  • 14.5.1 Strengths
  • 14.5.2 Weaknesses
  • 14.5.3 Opportunities
  • 14.5.4 Threats

15.0 REGENERATION TECHNOLOGIES

• 15.1 Company Overview
• 15.2 Products Offered
  • 15.2.1 Bone Graft Substitutes
  • 15.2.2 Maxillofacial Fixation and BGS
  • 15.2.3 Spinal AlloGrafts
  • 15.2.4 Sports Medicine AlloGrafts
• 15.3 Recent Events⁄Strategy
• 15.4 Financial Overview
• 15.5 S.W.O.T. Analysis
  • 15.5.1 Strengths
  • 15.5.2 Weaknesses
  • 15.5.3 Opportunities
  • 15.5.4 Threats

16.0 SMITH & NEPHEW

• 16.1 Company Overview
• 16.2 Products Offered
  • 16.2.1 Hyaluronic Acid Viscosupplementation
  • 16.2.2 Cartilage Repair Products
  • 16.2.3 Bone Graft Substitutes
• 16.3 Recent Events⁄Strategy
• 16.4 Financial Overview
• 16.5 S.W.O.T. Analysis
  • 16.5.1 Strengths
  • 16.5.2 Weaknesses
  • 16.5.3 Opportunities
  • 16.5.4 Threats

17.0 STRYKER CORPORATION

• 17.1 Company Overview
• 17.2 Products Offered
  • 17.2.1 Growth Factors
  • 17.2.2 Bone Graft Substitutes
• 17.3 Recent Events⁄Strategy
• 17.4 Financial Overview
• 17.5 S.W.O.T. Analysis
  • 17.5.1 Strengths
  • 17.5.2 Weaknesses
  • 17.5.3 Opportunities
  • 17.5.4 Threats

18.0 SYNTHES

• 18.1 Company Overview
• 18.2 Products Offered
  • 18.2.1 Spinal AlloGrafts
  • 18.2.2 Bone Graft Substitutes
• 18.3 Recent Events⁄Strategy
• 18.4 Financial Overview
• 18.5 S.W.O.T. Analysis
  • 18.5.1 Strengths
  • 18.5.2 Weaknesses
  • 18.5.3 Opportunities
  • 18.5.4 Threats

19.0 TUTOGEN

• 19.1 Company Profile
• 19.2 Products Offered
  • 19.2.1 Spinal AlloGrafts
• 19.3 Recent Events⁄Strategy
• 19.4 Financial Overview
• 19.5 S.W.O.T. Analysis
  • 19.5.1 Strengths
  • 19.5.2 Weaknesses
  • 19.5.3 Opportunities
  • 19.5.4 Threats

20.0 WRIGHT MEDICAL TECHNOLOGIES

• 20.1 Company Overview
• 20.2 Products Offered
  • 20.2.1 DBM Products
  • 20.2.2 Synthetic Bone Graft Substitutes
  • 20.2.3 Products in Developm en t
• 20.3 Recent Events⁄Strategy
• 20.4 Financial Overview
• 20.5 S.W.O.T. Analysis
  • 20.5.1 Strengths
  • 20.5.2 Weaknesses
  • 20.5.3 Opportunities
  • 20.5.4 Threats

21.0 ZIMMER

• 21.1 Company Overview
• 21.2 Products Offered
  • 21.2.1 Bone Graft Substitutes
• 21.3 Recent Events⁄Strategy
• 21.4 Financial Overview
• 21.5 S.W.O.T. Analysis
  • 21.5.1 Strengths
  • 21.5.2 Weaknesses
  • 21.5.3 Opportunities
  • 21.5.4 Threats
• 21.6 S.W.O.T. Analysis
  • 21.6.1 Strengths
  • 21.6.2 Weaknesses
  • 21.6.3 Opportunities
  • 21.6.4 Threats

APPENDIX A: LIST OF ABBREVIATIONS